'The dilemmas of breast cancer treatment and increased fracture risk' by Malik

Affiliations

¹ Department of Rheumatology, University Hospital, Angers Research Group on Bone Remodeling and BioMaterials, UPRES EA 4658, University Hospital, Angers, France bebouvard@chu-angers.fr.
² Department of Rheumatology, University Hospital, Angers Research Group on Bone Remodeling and BioMaterials, UPRES EA 4658, University Hospital, Angers, France.

Free article

Comment

B Bouvard et al. Ann Oncol. 2014 Aug.

Free article

. 2014 Aug;25(8):1664-5.

doi: 10.1093/annonc/mdu222. Epub 2014 Jun 11.

¹ Department of Rheumatology, University Hospital, Angers Research Group on Bone Remodeling and BioMaterials, UPRES EA 4658, University Hospital, Angers, France bebouvard@chu-angers.fr.
² Department of Rheumatology, University Hospital, Angers Research Group on Bone Remodeling and BioMaterials, UPRES EA 4658, University Hospital, Angers, France.

No abstract available

Comment on

Fracture incidence after 3 years of aromatase inhibitor therapy.
Bouvard B, Soulié P, Hoppé E, Georgin-Mege M, Royer M, Mesgouez-Nebout N, Lassalle C, Cellier P, Jadaud E, Abadie-Lacourtoisie S, Tuchais C, Vinchon-Petit S, Audran M, Chappard D, Legrand E. Bouvard B, et al. Ann Oncol. 2014 Apr;25(4):843-847. doi: 10.1093/annonc/mdu008. Epub 2014 Mar 7. Ann Oncol. 2014. PMID: 24608193
The dilemmas of breast cancer treatment and increased fracture risk.
Malik L. Malik L. Ann Oncol. 2014 Aug;25(8):1664. doi: 10.1093/annonc/mdu219. Epub 2014 Jun 11. Ann Oncol. 2014. PMID: 24920788 No abstract available.